SCHEMBL378032

SCHEMBL378032

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)C4CCCCC4)(c4ccccc4)CC3)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
POLB P06746 1/20 0.40
OPRK1 P41145 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NTRK1 P04629 1/20 0.38
P2RX3 P56373 1/20 0.38
LMNA P02545 1/20 0.38
SCD5 Q86SK9 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
ADRB3 P13945 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378776 0.92 TACR3 (0.40) OPRK1P2RX3GPR119F11
SCHEMBL378687 0.88 MGLL (0.44) TSHRPOLBP2RX3LMNAALDH1A1
SCHEMBL13092253 0.87 TSHR (0.44) TSHRPOLBNPC1RAB9ASCD5
SCHEMBL378915 0.86 TSHR (0.43) TSHROPRK1NPC1RAB9ASCD5
SCHEMBL13092256 0.85 TSHR (0.44) TSHRNPC1RAB9ASCD5ALDH1A1
SCHEMBL13092272 0.82 TACR3 (0.42) TSHRNPC1RAB9ALMNASCD5
SCHEMBL378669 0.82 TACR1 (0.41) TSHRNPC1LMNASCD5ALDH1A1
SCHEMBL379339 0.82 TSHR (0.42) TSHRSCD5CA12CA1CA2
SCHEMBL3103971 0.82 TSHR (0.43) TSHRNPC1RAB9ALMNASCD5
SCHEMBL396983 0.82 TACR1 (0.40) TSHRNPC1LMNASCD5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885POLB 2329/4885OPRK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.